Publicado
Results of the implementation of the PETHEMA LPA 99 protocol for treating children with acute promyelocytic leukemia in Bogotá, Colombia
Resultados de la implementación del protocolo PETHEMA LPA 99 en el tratamiento de niños con leucemia promielocítica aguda en Bogotá, Colombia
DOI:
https://doi.org/10.15446/revfacmed.v69n2.80152Palabras clave:
Acute Promyelocytic Leukemia, Children, Survival, Treatment (en)Leucemia promielocitica aguda, Niños, Supervivencia, Tratamiento (es)
Descargas
Introduction: In the United States, between 4 and 8% of children with acute myeloid leukemia have acute promyelocytic leukemia (APL), but a higher incidence of this malignancy has been reported in Latin America (20%-28%). The implementation of the PETHEMA LPA 99 protocol, designed for the treatment of APL in adults, has shown an overall survival (OS) >80%.
Objective: To describe the results obtained after the implementation of the PETHEMA LPA 99 protocol to treat children with APL at the Fundación Hospital Pediátrico La Misericordia in Bogotá, D.C., Colombia.
Materials and methods: Descriptive and retrospective cohort study. The medical records of 30 pediatric patients (<18 years) with APL, who were treated using the PETHEMA LPA 99 protocol between January 2005 and December 2012, were reviewed. Data on the following variables were obtained: early death, death during induction therapy, OS, event-free survival (EFS), and relapse.
Results: The male sex was predominant (60%) among the 30 patients included in the study. Regarding risk classification, 13 (43%) were classified as high-risk patients, 12 (40%) as medium-risk, and 5 (17%) as low-risk. Seven individuals died: 2 before receiving cancer treatment, 2 during induction therapy, and 3 after relapse. Relapse was reported in 5 patients. There were no deaths during the consolidation or maintenance phases. OS was 75.4% (95%CI: 55.1-87.5) and EFS was 64.3% (95%CI: 40-80.5). Moreover, OS at 11 years was 80%, 91.7%, and 59.2% for low-risk, intermediate-risk, and high-risk patients, respectively. The median follow-up time was 6.35 years (0-11.43 years).
Conclusions: In general, the implementation of the PETHEMA LPA 99 protocol to treat APL in the study population showed very satisfactory results. Therefore, its use in pediatric population is recommended, taking into account the adjustments described in the protocol regarding the characteristics of this age group.
Introducción. En Estados Unidos de América, entre 4 y 8% de niños con leucemias mieloides agudas tienen leucemia promielocítica aguda (LPA), mientras que en Latinoamérica se ha descrito una mayor incidencia de esta neoplasia (20-28%). La implementación del protocolo PETHEMA LPA 99, diseñado para el tratamiento de LPA en adultos, ha mostrado una supervivencia global (SG) >80%.
Objetivo. Describir los resultados de la aplicación del protocolo PETHEMA LPA 99 en el tratamiento de niños con LPA en la Fundación Hospital Pediátrico la Misericordia, en Bogotá D.C., Colombia.
Materiales y métodos. Estudio de cohorte descriptivo y retrospectivo. Se revisaron las historias clínicas de 30 pacientes pediátricos (<18 años) con LPA que recibieron tratamiento mediante el protocolo PETHEMA LPA 99 entre enero de 2005 y diciembre de 2012. Se obtuvieron datos sobre las siguientes variables: muerte temprana, muerte en terapia de inducción, SG, supervivencia libre de evento (SLE) y recaída.
Resultados. De los 30 pacientes, la mayoría eran de sexo masculino (60%). Respecto a la clasificación de riesgo, 13 (43%) fueron clasificados como pacientes de riesgo alto; 12 (40%), de riesgo intermedio, y 5 (17%), de riesgo bajo. 7 individuos murieron: 2 antes del tratamiento oncológico, 2 durante la terapia de inducción y 3 luego de presentar recaída. Se reportó recaída en 5 pacientes. No hubo muertes durante las fases de consolidación o de mantenimiento. La SG fue de 75.4% (IC95%: 55.1-87.5) y la SLE fue de 64.3% (IC95%: 40-80.5). La SG a 11 años fue de 80%, 91.7% y 59.2% para los pacientes de riesgo bajo, riesgo intermedio y riesgo alto, respectivamente. La mediana de seguimiento fue 6.35 años (0-11.43 años).
Conclusiones. En general, la implementación del protocolo PETHEMA LPA 99 en el tratamiento de la LPA en la población de estudio mostró resultados muy satisfactorios, por lo que se recomienda su uso en población pediátrica, teniendo en cuenta los ajustes recomendados por el protocolo en relación con las características de este grupo etario.
Referencias
Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 7th ed. Lippincott Williams&Wilki; 2015.
Melo RAM, de Vasconcellos JF, Melo FCBC, Machado CGF, Lacerda TMS, Souto FR. PML-RAR alpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients. Clin Lab Haematol. 2006;28(2):126-29. https://doi.org/ccq5km.
Rego EM, Jacomo RH. Epidemilogy and treatment of Acute Promyelocytic Leukemia in Latin America. Mediterr J Hematol Infect Dis. 2011,3(1):e2011049. https://doi.org/fbfbkm.
Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 1999;15(5):179-84. https://doi.org/fgmzgz.
Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-43. https://doi.org/cdh7k9.
Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008;112(8):3130-4. https://doi.org/bh7dc4.
Yamamoto M, Okada K, Akiyama H, Kurosu T, Miura O. Evaluation of the efficacy of maintenance therapy for low-to-intermediate-risk acute promyelocytic leukemia in molecular remission: A retrospective single-institution study. Mol Clin Oncol. 2015;3(2):449-53. https://doi.org/f3d8.
Yoo ES. Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. Korean J Pediatr. 2011;54(3):95-105. https://doi.org/c4d2r7.
Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Haznedaroglu IC, Aksu S, et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res. 2010;34(12):e317-9. https://doi.org/bz4jv9.
Jeddi R, Ghédira H, Menif S, Ben Neji H, Ben Amor R, Kacem K, et al. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience. Hematology. 2010;15(4):204-9. https://doi.org/bpdxzt.
Ortega JJ, Madero L, Martín G, Verdeguer A, García P, Parody R, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005;23(30):7632-40. https://doi.org/b8qqbf.
Rego EM, Kim HT, Ruiz-Argüelles GJ, Uriarte Mdel R, Jacomo RH, Gutiérrez-Aguirre H, et al. The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). Hematology. 2012;17(Suppl 1):S36-8. https://doi.org/f3fc.
Colombia. Ministerio de Salud y Protección Social (MinSalud). Guía de práctica clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas y adolescentes. Para uso de profesionales de salud. Guía No. 9. Bogotá D.C.: MinSalud; 2013 [cited 2019 Oct 20]. Available from: https://bit.ly/399U8Pc.
World Medical Association (WMA). WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. Fortaleza: 64th WMA General Assembly; 2013.
Colombia. Ministerio de Salud. Resolución 8430 de 1993 (octubre 4): Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá D.C.; octubre 4 de 1993 [cited 2019 Jul 28]. Available from: https://bit.ly/3lJ1gXE.
Aksu T, Fettah A, Bozkaya İO, Baştemur M, Kara A, Çulha VK, et al. Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey. Mediterr J Hematol Infect Dis. 2018;10(1):e2018045. https://doi.org/gdvxpz.
Jastaniah W, Alsultan A, Al Daama S, Ballourah W, Bayoumy M, Al-Anzi F, et al. Clinical characteristics and outcome of childhood acute promyelocitic leukemia (APL) in Saudi Arabia: a multicenter SAPHOS leukemia group study. Hematology. 2018;23(6):316-23. https://doi.org/gg74k7.
Takahashi H, Watanabe T, Kinoshita A, Yuza Y, Moritake H, Terui K, et al. High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group. Br J Haematol. 2016;174(3):437-43. https://doi.org/f8zmxf.
Lins MM, Mello MJG, Ribeiro RC, De Camargo B, de Fátima Pessoa Militão de Albuquerque M, Thuler LCS. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country. Ann Hematol. 2019;98(6):1403-11. https://doi.org/f3fq.
Dorantes-Acosta E, Medina-Sanson A, Jaimes-García Y, López-Martínez B. Clinical features and treatment outcomes of pediatric acute promyelocytic leukemia in a Mexican pediatric hospital. Rev Investig Clin. 2013;65(5):392-8.
Lengfelder E, Saussele S, Weisser A, Büchner T, Hehlmann R. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol. 2005;56(2):261-74. https://doi.org/dsrtf4.
Sultan S, Irfan SM, Ashar S. Acute Promyelocytic Leukemia: a Single Center Study from Southern Pakistan. Asian Pac J
Cancer Prev. 2015;16(17):7893-5. https://doi.org/f3fs.
Chen C, Huang X, Wang K, Chen K, Gao D, Qian S. Early mortality in acute promyelocytic leukemia: Potential predictors. Oncol Lett. 2018;15(4):4061-9. https://doi.org/f3ft.
McDonnell MH, Smith ET, Lipford EH, Gerber JM, Grunwald MR. Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype. Hematol Oncol Stem Cell Ther. 2017;10(1):35-8. https://doi.org/f3fv.
Orfao A, Chillón MC, Bortoluci AM, López-Berges MC, García-Sanz R, Gonzalez M, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARa gene rearrangements. Haematologica. 1999;84(5):405-12.
Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117(6):1799-805. https://doi.org/bd4sb7.
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, et al. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Cancer Sci. 2014;105(1):97-104. https://doi.org/f5rw33.
Dimensions
PlumX
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2020 Revista de la Facultad de Medicina
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-
